ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 576,75
-0,73%
Dow Jones
40 211,72
0,00%
DAX
18 500,58
-0,54%
Brent Oil
82,945
-1,65%
Bitcoin
63 820,87
-1,59%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
06/02/201722h53Business WireTeva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez VigodmanNYSE:TEVATeva Pharmaceutical Industries Ltd
02/02/201714h14Edgar (US Regulatory)Report of Foreign Issuer (6-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
02/02/201714h00Business WireTeva Confirms Generic Victoza® Patent Challenge in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
01/02/201721h01Business WireTeva to Report Fourth Quarter 2016 Financial Results on February 13, 2017NYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/201715h48Dow Jones NewsHot Stocks to Watch in the U.S. and CanadaNYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/201700h52Business WireTeva Confirms District Court Decision in COPAXONE® 40 mg/mL Patent TrialNYSE:TEVATeva Pharmaceutical Industries Ltd
30/01/201714h00Business WireTeva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of AsthmaNYSE:TEVATeva Pharmaceutical Industries Ltd
18/01/201714h00Business WireTeva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated with Propriet...NYSE:TEVATeva Pharmaceutical Industries Ltd
09/01/201713h30Business WireTeva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European Commission ApprovalNYSE:TEVATeva Pharmaceutical Industries Ltd
06/01/201722h01Business WireTeva to Present at the 35th Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
06/01/201713h30Business WireTeva Provides 2017 Financial OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
05/01/201722h01Business WireTeva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017NYSE:TEVATeva Pharmaceutical Industries Ltd
03/01/201721h44Business WireGPM Reminds Investors of the January 5 Deadline in the Class Action Lawsuit Against Teva Pharmaceutical Industries LimitedNYSE:TEVATeva Pharmaceutical Industries Ltd
30/12/201616h30Business WireJanuary 5 Deadline Alert: Law Offices of Howard G. Smith Reminds Teva Pharmaceutical Industries Limited Investors of Upcoming...NYSE:TEVATeva Pharmaceutical Industries Ltd
28/12/201600h34Business WireGlancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Teva Pharmaceutical Industries LimitedNYSE:TEVATeva Pharmaceutical Industries Ltd
23/12/201609h02Dow Jones NewsTeva Settles Charges in U.S. -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
23/12/201600h28Dow Jones NewsADRs End LowerNYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/201621h48Dow Jones NewsTeva Settles Foreign Corruption Probe for $519 Million -- 2nd UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/201618h05Dow Jones NewsTeva Settles Foreign Corruption Probe for $519 Million--UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/201616h31Dow Jones NewsTeva Settles Foreign Corruption Probe for $519 millionNYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/201615h15Business WireTeva Reaches Settlement with Government on FCPANYSE:TEVATeva Pharmaceutical Industries Ltd
17/12/201613h05PR Newswire (US)SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Teva Phar...NYSE:TEVATeva Pharmaceutical Industries Ltd
17/12/201604h50Business WireTEVA SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess o...NYSE:TEVATeva Pharmaceutical Industries Ltd
14/12/201620h28Business WireGlancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceuticals Investors & E...NYSE:TEVATeva Pharmaceutical Industries Ltd
08/12/201604h00Business WireDEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Lo...NYSE:TEVATeva Pharmaceutical Industries Ltd
07/12/201615h05Business WireTeva to Present at the Citi 2016 Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/201612h30Business WireTeva reçoit un avis positif pour l'étiquette du COPAXONE® en EuropeNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/201608h00Business WireTeva erzielt positives Ergebnis für Etikett von COPAXONE® in EuropaNYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/201608h00Business WireTeva Receives Positive Outcome for COPAXONE® Label in EuropeNYSE:TEVATeva Pharmaceutical Industries Ltd
05/12/201622h01Business WireTeva Appoints Dipankar Bhattacharjee as President & Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi...NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

BIT
P1HLJ4
BNP Paribas Issuance
NASDAQ
GRRF
LSE
ESG
Eservglobal
NASDAQ
UBXG
U BX Technology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés